vimarsana.com
Home
Live Updates
FDA Grants Fast Track Status to SLS009 for Relapsed/Refracto
FDA Grants Fast Track Status to SLS009 for Relapsed/Refracto
FDA Grants Fast Track Status to SLS009 for Relapsed/Refractory Acute Myeloid Leukemia
The FDA has granted fast track designation to SLS009 for use as a potential therapeutic option in patients with relapsed or refractory acute myeloid leukemia.
Related Keywords
Angelos Stergiou ,
Life Sciences Group Inc ,
Life Sciences ,
Sciences Group ,
Fda ,
Sls009 ,
Aml ,
Relapsed Or Refractory Acute Myeloid Leukemia ,
Nct04588922 ,